curry Implant Can Slow Down Breast Cancer Development

In a new study, researchers from the University of Louisville, Kentucky developed a "curry implant" in the form of a dissolvable capsule. The team tested the capsules by implanting them into mice models and discovered that the spice was capable of reducing tumor size. "Curcumin is widely known for its anti-oxidant, anti-inflammatory and anti-proliferative activities in cell culture studies. However, poor oral bioavailability limited its efficacy in animal and clinical studies. Recently, we developed polymeric curcumin implants that circumvents oral bioavailability issues, and tested their potential," the authors wrote. The capsules were dissolvable. The researchers implanted two capsules into female mice that had tumors. Another group of mice were given curry spice as a part of their daily diet. The researchers monitored the mice's tumor growth over the next four months. The researchers found that simply eating a diet with curry spice had no positive or negative effects on tumor growth. More information at http://www.counselheal.com/articles/8607/20140210/curry-implant-can-slow-down-breast-cancer-development.htm.





Curcumin for Cancer: Part Two





Figure 5. Curcumin activity. Curcumin inhibits the growth/viability of human multiple myeloma cell line U266 and bone marrow CD138+ multiple myeloma cells (A-D). Cell line U266 (A) or enriched CD138+ cells (2 x 104/0.1 mL) from bone marrow aspirates of multiple myeloma patients (nos. 7, 9, and 10) (B-D) were cultured in the absence or presence of the indicated concentrations of curcumin for 24 hours, and cell viability
was measured by MTT assay (A-B) or standard trypan blue dye exclusion method (C,D) as described. Curcumin inhibits the expression of Bcl-2 and Bcl-XL proteins in human multiple myeloma cell line U266 (E) and bone marrow CD138+ multiple myeloma cells (F). A total of 2 x 106 U266 cells (E) or CD138+ multiple myeloma cells (F) were treated with curcumin (50 M) for the indicated times, prepared the cytoplasmic extracts, resolved the 50 g cytoplasmic extracts on 10% SDS-PAGE cervical cancer treatment gel, electrotransferred on a nitrocellulose membrane, and probed for Bcl-2 and Bcl-XL by Western blot analysis. {beta}-actin was used as a loading control. Values represent the mean SD of triplicate cultures. These data show that even continuous exposure of at least 10 micromolar curcumin is required to have any detectable effects in killing multiple myeloma cells news and that 50 micromolar is better, although in cervical mallignant melanoma no case does that very high concentration eradicate the tumor cells in any of the experiments. So, what would be the effect on these cancer cells of 0.5 micromolar curcumin for barely the length of one hour as shown earlier in the human pharmacokinetic study? More information at http://scienceblogs.com/terrasig/2006/10/04/curcumin-for-cancer-part-two-1/.